Abstract. The B7 family, the most common family of secondary signaling molecules, consists of eight cell-surface proteins, which regulate the T-cell mediated immune response by delivering co-inhibitory or co-stimulatory signals through their corresponding ligands. Among them, natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, also known as B7H6) has been reported as a new member, and is involved in tumor progression of various types of human cancer. However, the role of B7H6 in triple-negative breast cancer (TNBC) remains unknown. In the present study, western blotting was performed to determine the protein expression levels of B7H6 in a normal mammary epithelial cell line (MCF-10A), non-TNBC breast cancer cell lines (MCF-7 and AU565) and TNBC cell lines (MDA-MB-231 and MDA-MB-468). B7H6 was knocked down using small interfering RNA, and an MTT assay was performed to determine proliferation ability, flow cytometry was used to analyze apoptosis, and Transwell and wound-healing assays were performed to measure migration ability. Expression of proliferation-associated proteins (SMAD family member 4 and β-catenin) and apoptosis-associated proteins (BCL2 associated X, BCL2 apoptosis regulator and caspase-3) were analyzed by western blotting. The results demonstrated that B7H6 was highly expressed in TNBC cells, and that knockdown of B7H6 inhibited cell proliferation and migration, and promoted apoptosis. Furthermore, the results revealed that proliferation and apoptosis-associated proteins were altered in the B7H6-knockdown MDA-MB-231 cells. In conclusion, the present study demonstrated that B7H6 may have significant roles in the regulation of cell proliferation, apoptosis and migration of TNBC cells.

Introduction

Breast cancer (BC) is one of the most common types of cancer worldwide, accounting for ~20-23% of total cancer cases, and the incidence is increasing each year (1,2). Although the diagnostic techniques and therapeutic strategies have improved over the past decades, BC remains the leading cause of cancer death in females worldwide (3).

Triple-negative breast cancers (TNBCs), accounting for ~25% of BC cases, are characterized by tumors that lack expression of the estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor receptor 2 (HER2) (4,5). Because the majority of basal-like cancers are also ER-, PR-, and HER2-negative (~80%), it has been suggested that the triple-negative and basal-like phenotypes are effectively synonymous, but data from immunohistochemical analysis have revealed that this is not the case (6-8). Triple-negative is a phenotype that encompasses more than one molecular subtype: its major components are the basal-like, normal, and claudin-low molecular subtypes, including BRCA1-deficient breast tumors (9). Hormone receptor-positive breast tumors are treated with endocrine manipulations, such as tamoxifen and aromatase inhibitors (10). However, patients with TNBC cannot benefit from endocrine therapy because of the lack of ER, PR, and HER2 expression. The current treatment options for TNBC are limited, and include surgery, radiation therapy, and systemic treatment. Chemotherapy is currently the only approved systemic treatment for TNBC, which is frequently accompanied by considerable side effects (1,11). Therefore, there is an urgent need to investigate the molecular mechanisms and to explore novel diagnostic and therapeutic strategies for TNBC.

The B7 family of proteins consists of co-stimulatory or co-inhibitory molecules that are expressed mainly on the cell surface of antigen presenting cells and serve a key role in the regulation of the immune system (12,13). Among the B7 family, natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, also known as B7H6) was identified as a tumor-specific ligand for the natural cytotoxicity triggering receptor 3 (NCR3) (14). It has been reported that B7H6 is expressed in various types of tumor cells, including lung, ovarian and renal cell cancer, but not expressed in normal tissues (14,15). Thus, B7H6 holds therapeutic potential for cancer, but its exact role in cancer is not fully elucidated yet. In specific, the mechanisms by which B7H6 may affect tumor progression have not been identified fully in TNBC cells.

Key words: B7 family, natural killer cell cytotoxicity receptor 3 ligand 1, triple-negative breast cancer, tumor progression

Correspondence to: Dr Shengrong Sun, Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, 236 Jiefang Road, Wuhan, Hubei 430060, P.R. China
E-mail: sunshengrong6523@126.com

Received April 28, 2017; Accepted January 22, 2018

DOI: 10.3892/ol.2018.8689
In the present study, it was hypothesized that knockdown of B7H6 might be involved in inhibiting tumor progression of TNBC cells. Suppression of B7H6 could be used as a potential target for treatment of TNBC. Therefore, the role of B7H6 in cell viability, apoptosis and migration of TNBC cells was investigated.

Materials and methods

Cell culture. Human normal mammary epithelial cell line (MCF-10A), BC cell lines (MCF-7, AU565), and TNBC cell lines (MDA-MB-231, MDA-MB-468) were all obtained from the American Tissue Cell Culture collection (ATCC; Manassas, VA, USA). MCF-10A cells were maintained in Dulbecco's modified Eagle's medium (DMEM)/F12 medium (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10 µg/ml insulin (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany), 100 ng/ml choloroenteroxin, 0.5 µg/ml hydrocortisol, and 20 ng/ml epidermal growth factor (EGF). MCF-7 and AU565 cells were cultured in RPMI 1640 (Invitrogen; Thermo Fisher Scientific, Inc.) with 10% fetal bovine serum (FBS; Sigma-Aldrich; Merck KGaA). MDA-MB-231 and MDA-MB-468 cells were propagated in DMEM/H-21 (Invitrogen; Thermo Fisher Scientific, Inc.) at 4˚C or on ice for 2 h. Total proteins were prepared using the Extraction kit (Beyotime Institute of Biotechnology, Shanghai, China). The antibodies used in the present study were: anti-GAPDH (1:1,000; Santa Cruz Biotechnology, Inc., Dallas, TX, USA), anti-SMAD family member 4 (SMAD4; 1:300; ab204759; Abcam, Cambridge, MA, USA), anti-β-Catenin (1:1,000; ab32572; Abcam), anti-BCL2 associated X (Bax; 1:1,000; ab32503; Abcam), anti-BCL2 apoptosis regulator (Bcl-2; ab32124; 1:1,000; Abcam), and anti-Caspase-3 (1:1,000; ab13585; Abcam).

Cell viability assay (MTT assay). MTT assay was performed in order to evaluate the effects of B7H6 siRNA on TNBC cell lines, as previously described (16). Briefly, cells were harvested with trypsin and seeded at a concentration of 3x10^5 cells/well into a 96-well plate. Then, 20 µl of MTT reagent was added to each well, and incubated at 37˚C for 4 h, followed by the addition of 150 µl dimethyl sulfoxide. Finally, absorbance was determined by using a microplate reader at 490 nm (Sunrise; Tecan Group Ltd., Männedorf, Switzerland) at 48 h.

Flow cytometry analysis. Cell apoptosis was investigated by flow cytometry using Annexin V/propidium iodide (PI) double staining (BD Biosciences, Franklin Lakes, NJ, USA). The cells were plated onto 6-well plates at a concentration of 1x10^6 cells/well. Following incubation for 24 h, cells were washed twice with cold PBS, and resuspended in 500 µl binding buffer containing 5 µl fluorescein isothiocyanate (FITC)-labeled Annexin V and 5 µl PI for at least 10 min at room temperature in the dark. Finally, cells were analyzed by flow cytometry and data were analyzed using Cell Quest Pro software (BD Biosciences).

Transwell assay. The cell migration assay was performed in 6-well Transwell chambers with 8-µm pore size polycarbonate membranes (Corning Inc., Corning, NY, USA). Cells were suspended in serum-free medium at a density of 1x10^6 cells/well, then 100 µl of this cell suspension was seeded in the upper chamber. The lower chamber was filled with 500 µl medium supplemented with 20% fetal calf serum (Gibco; Thermo Fisher Scientific, Inc.). Following 24 h of incubation at 37˚C in 5% CO_2, cells on the upper surface of the membrane were removed, and the lower surface of the inserts was fixed in methanol for 10 min and stained with crystal violet. The cells that had migrated to the lower surface were photographed and measured using an inverted phase contrast microscope (magnification, x40; Olympus Corporation, Tokyo, Japan).

Wound-healing assay. Cells were seeded in 6-well plates at the density of 1.5x10^5 cells/well, and cultured overnight until confluent. Then the cells were treated with siRNAs (50 nM negative control siRNA or 50 nM B7H6 siRNA) for 48 h. A straight scratch was made through the confluent cells with a pipette tip. Cells were washed twice with PBS, and images (magnification, x100) were captured immediately as baseline. Fresh medium was then added and images of the same location were captured at 48 h. The ratio of the remaining wound area relative to the initial wound area was calculated using Image-Pro Plus software (version 6.0; Media Cybernetics, Bethesda, MD, USA).
Statistical analysis. Data are presented as mean ± standard deviation. SPSS 21.0 software (IBM Corp., Armonk, NY, USA) and GraphPad (GraphPad Software, Inc., La Jolla, CA, USA) were used to conduct the analysis. Statistical differences between two groups were examined with unpaired Student's t-test and multiple groups were compared using one-way analysis of variance followed by Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

B7H6 is highly expressed in TNBC cell lines. To investigate the potential biological roles of B7H6 in TNBC, the expression levels of B7H6 were examined using western blot analysis in a normal mammary epithelial cell line (MCF-10A), a ER+/PR+ breast cancer cell line (MCF-7), a HER2+ breast cancer cell line (AU565), and two triple-negative breast cancer cell lines (MDA-MB-231 and MDA-MB-468). GAPDH was used as the internal standard. (B) Quantitative data analysis. B7H6, natural killer cell cytotoxicity receptor 3 ligand 1.

B7H6 knockdown inhibits cell proliferation and promotes apoptosis in TNBC cells. To further assess the biological function of B7H6 in TNBC cells, the expression of B7H6 was silenced in MDA-MB-231 cells, and the effects of B7H6 silencing on cell proliferation were examined using the MTT assay. First, the efficiency of the B7H6-specific siRNA was confirmed by western blotting. The results demonstrated that transfection of the MDA-MB-231 cells with the B7H6 siRNA resulted in a marked downregulation of B7H6 expression compared with control (Fig. 2A). The results from the MTT assay indicated that knockdown of B7H6 significantly inhibited the proliferation of MDA-MB-231 cells compared with cells transfected with negative control siRNA (Fig. 2B), suggesting that B7H6 knockdown suppresses cell migration in MDA-MB-231 cells.

B7H6 knockdown upregulates the expression of β-catenin, caspase-3, and Bax, and downregulates the expression of SMAD4 and Bcl-2 in TNBC cells. To further confirm the effects of B7H6 on cell proliferation and apoptosis, the expression of several proliferation and apoptosis-related proteins was examined in TNBC cells transfected with B7H6 siRNA. Western blot analysis revealed that SMAD4 expression was downregulated and β-catenin expression was upregulated following B7H6 knockdown, compared with cells transfected with negative control siRNA (Fig. 4), indicating that B7H6 promoted proliferation in TNBC cells. In addition, the results demonstrated that knockdown of B7H6 increased the production of caspase-3 and Bax, and decreased the production of Bcl-2 in TNBC cells (Fig. 4), suggesting that B7H6 inhibited TNBC cell apoptosis.

B7H6 knockdown suppresses cell migration in MDA-MB-231 cells. To validate the effects of B7H6 on cell migration, Transwell and wound-healing assays were conducted in MDA-MB-231 cells transfected with B7H6 or negative control siRNA. Results from the Transwell assay demonstrated that cell migration was significantly decreased in the B7H6 knockdown group compared with the control group (Fig. 3A). In the wound-healing assay, the scratch healed slower in B7H6-knockdown MDA-MB-231 cells compared with the control group (Fig. 3B), suggesting that B7H6 inhibits cell migration in TNBC cells.

Discussion

Despite an overall decreased mortality of TNBC, the incidence appears to be on the rise and the prognosis remains poorer than the other types of BC (17). Given the lack of molecular targets, traditional treatments have limited effect, and the possibility of metastasis of TNBC to visceral sites, including the brain, is higher than the other subtypes (18). Recent studies have demonstrated that EGF receptor (EGFR) and vascular endothelial growth factor (VEGF) are involved in the progression of TNBC cells in vitro (19). It was reported that bevacizumab, an anti-angiogenic agent that targets VEGF, could induce a significant improvement in progression-free survival of TNBC (20). Similar reports have suggested that EGFR is expressed on approximately half of the basal-like BC cells, and is indispensable for the proliferation of basal-like cell lines (21,22). Recently, an antibody against
EGFR (cetuximab) was designed to treat breast cancer (23). Currently, the therapeutic strategies for TNBC primarily include surgery (breast conservation therapy and mastectomy) and chemotherapy (24,25). But outcome still remains poor for
patients with TNBC and therefore targeted agents need to be investigated to explore novel treatments for TNBC.

The immune system has been demonstrated to crosstalk with tumor cells, and the aberrant expression of co-stimulatory or co-inhibitory molecules that belong to the B7 family has been considered to be involved in the suppression of antitumor immunity (26,27). Therefore, the relationship between the B7 family and antitumor immunity is currently being studied to explore potentially novel effective therapeutic targets for various human cancers. Despite the undetermined function of B7H3, experiments with tumor models tend to support a co-stimulatory role in antitumor immunity. For example, mouse P815 tumor cells transfected with B7H3 display enhanced immunogenicity (28). It was reported that B7H4 is overexpressed in human BCs, and knockdown of B7H4 by specific siRNA induced tumor cell apoptosis, suggesting a co-inhibitory role of B7H4 in BC cells (29). B7H6, a recently discovered member of the B7 family, has been reported to be expressed on tumors despite its absence in normal tissues, suggesting that it may be a potential target for cancer treatment (14). B7H6 was identified as a tumor-specific ligand for NCR3 (14). It has been reported that B7H6 mRNA expression is upregulated in leukemia and gastrointestinal stromal tumors and associated with clinical observations of NCR3-mediated immunosurveillance in these tumors (30,31). However, the mechanism by which B7H6 affects tumor progression has not been identified completely in TNBC cells. Previously, it has been reported that several types of primary human tumors, including lymphoma, leukemia, ovarian cancer, breast cancer, renal cell carcinoma, various sarcomas and brain tumors, express high levels of B7H6 mRNA (32).

To investigate the exact role of B7H6 in BC first the expression levels of B7H6 were examined in several BC cell lines. The results demonstrated that B7H6 was highly expressed in the TNBC cell lines compared with non-TNBC and normal human mammary epithelial cell lines. To determine the function of B7H6 in TNBC cells, cell viability, apoptosis, and migration were measured following B7H6 knockdown in TNBC cells. The results demonstrated that B7H6 promoted TNBC cell proliferation and migration, and inhibited apoptosis.

Previous studies have demonstrated that SMAD4 is a tumor suppressor involved in the proliferation of many human cancers, including gastric, colorectal, and breast cancers (33-35). SMAD4 suppresses invasiveness and mediates reversion of SW480 cells from a mesenchymal-like to a polarized epithelial phenotype, with features of enterocyte-like differentiation (36). Therefore, the present study investigated whether B7H6 could regulate the production of SMAD4, and western blot analysis revealed that B7H6 knockdown decreased the expression of SMAD4. Because SMAD4 was reported to prevent tumor progression by diminishing the β-catenin signal, production of β-catenin was also measured and revealed to be upregulated following B7H6 knockdown in TNBC cells. Furthermore, the production of several apoptosis-related proteins was examined in B7H6-knockdown TNBC cells, and the results demonstrated that caspase-3 and Bax were upregulated, while Bcl-2 was downregulated. These data further confirmed the inhibitory effects of B7H6 in TNBC cells. The present results suggest that B7H6 might have important roles in the regulation of cell proliferation, apoptosis and migration in TNBC cells.

Acknowledgements
Not applicable.

Funding
No funding was received.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.
Authors' contributions

BZ and SS designed the study. JS, XY and JL performed the experiments. YY and FY analyzed the data. BZ wrote the manuscript. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Kumar P and Aggarwal R: An overview of triple-negative breast cancer. Arch Gynecol Obstet 293: 247-269, 2016.

2. Boyle P: The globalisation of cancer. Lancet 368: 629-630, 2006.

3. Autier P, Boniol M, LaVecchia C, Vatten L, Gavin A, Héry C and Heanue M: Disparities in breast cancer mortality trends between 30 European countries: Retrospective trend analysis of WHO mortality database. Br Med J 341: c6260, 2010.

4. Baur K, Brown M, Cress RD, Parise CA and Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the California cancer registry. Cancer 101: 1721-1728, 2007.

5. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML and Perou CM: The triple-negative paradox: Primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13: 2329-2334, 2007.

6. Sotiriou C and Pusztai L: Gene-expression signatures in breast cancer. N Engl J Med 360: 771-781, 2009.

7. Kreike B, van Koonenmewh H, Horlings H, Weigelt B, Peters H, Bartelink H and van de Vijver MJ: Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 9: R65, 2007.

8. Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med 363: 1938-1948, 2010.

9. Krishnamurthy S, Poornima R, Challa VR and Goud YG: Triple negative breast cancer-our experience and review. Indian J Surg Oncol 3: 12-16, 2012.

10. Sethi S, Sarkar FH, Ahmed Q, Bandypadhyay S, Nahile ZA, Semaan A, Sakr W, Munkarah A and Ali-Fehmi R: Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma. Transl Oncol 4: 223-226, 2011.

11. Pardo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, van Huffel S, van Laarhoven HW, Luts J, Monleon D, et al: Triple-negative breast cancer: Present challenges and new perspectives. Mol Oncol 4: 209-229, 2010.

12. Collins M, Ling V and Carreno BM: The B7 family of immune-regulatory ligands. Genome Biol 6: 223, 2005.

13. Flajnik MF, Tlapakovka T, Criscitiello MF, Krylow V and Ohta Y: Evolution of the B7 family: Co-evolution of B7H6 and NKp30, identification of a new B7 family member, B7H7, and of B7's historical relationship with the MHC. Immunogenetics 64: 571-590, 2012.

14. Brandt CS, Baratin M, Yi EC, Kennedy J, Gao Z, Fox B, Haldeman B, Ostrander CD, Kaifu T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676, 2007.

15. Sizipopiku KP and Cotebigh M: The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 16: 104-107, 2007.

16. Wang G, Ye Y, Yang X, Liao H, Zhao C and Liang S: Expression-based in silico screening of candidate therapeutic compounds for lung adenocarcinoma. PLoS One 6: e14573, 2011.

17. Pusztai L: Triple-negative breast cancer: A short review. Am J Clin Oncol 33: 637-645, 2010.

18. Herold CI and Anders CK: New targets for triple-negative breast cancer. Oncology (Williston Park) 27: 846-854, 2013.

19. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkel T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676, 2007.

20. Sizipopiku KP and Cotebigh M: The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 16: 104-107, 2007.

21. Sizipopiku KP and Cotebigh M: The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies. Breast 16: 104-107, 2007.